Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.

##plugins.themes.academic_pro.article.sidebar##

Published Oct 26, 2015
Download
pdf
Vol. 93 No. 6 (2015): Issue Jun 2015

##plugins.themes.academic_pro.article.main##

Nour Elleuch
Rym Ennaifer
Service de Gastro-entérologie Hôpital H. Thameur Tunis
Hayfa Romdhane
Service de Gastro-entérologie A. Hôpital la Rabta. Tunis
Meryam Cheikh
Rania Hefaiedh
Wassila Bougassas
Houda Ben Nejma
Najet Bel Hadj

Abstract

Introduction: Sorafenib, an oral multikinase inhibitor, has recentlybeen shown to improve overall survival in patients with advanced hepatocellular carcinoma (HCC) but only a handful of reports of complete remission on sorafenib have been issued.
Case report: We report an intriguing case of advanced HCC complicating HCV infection with cirrhosis, in which the patient achieved complete remission by prolonged administration of sorafenib.
Conclusion: Identifying factors that could be associated with good response to this therapy are needed.

Keywords:

Hepatocellular carcinoma - Sorafenib - treatment

##plugins.themes.academic_pro.article.details##

References

  1. Raoul JL, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol. 2012;56:1080-8.
  2. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
  3. Min Su Kim, Young-Joo Jin, Jin-Woo Lee,et al. Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report. World J Gastrointest Oncol. 2013;5:38-42.
  4. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
  5. Tarantino L, Francica G, Sordelli I, et al. Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine needle biopsy. Abdom Imaging. 2006;11:537-44.
  6. Piscaglia F, Gianstefani A, Ravaioli M, et al. Bologna Liver Transplant Group. Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transpl. 2010;11:658-67.
  7. Novi M, Lauritano EC, Piscaglia AC, et al. Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am J Gastroenterol. 2009;104:1852-4.
  8. Yang MY, Jeong SW, Kim DK, et al. Treatment of hepatocellular carcinoma with portal vein thrombosis by sorafenib combined with hepatic arterial infusion chemotherapy. Gut Liver. 2010;4:423-7.
  9. Jeong SW, Jang JY, Shim KY, et al. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. Gut Liver. 2013;6:696-703.
  10. Li Q, Xu B, Fu L, Hao XS. Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. J Exp Clin Cancer Res.2006;25:403-9.
  11. Natori T, Yamaguchi M. Complete response after sorafenib therapy plus zoledronic acid for advanced hepatocellular carcinoma with bone metastasis - a case report. GanTo Kagaku Ryoho. 2013;40:635-7.
  12. Shiozawa K, Watanabe M, IkeharaT, et al. Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report. Oncol Lett. 2014;7:50-2.